EPCO-22. DIVERGENT MEDULLOBLASTOMA CHROMATIN STATES DISCLOSE KDM2B AS A SELECTIVE DEPENDENCY
Abstract Medulloblastoma (MB) is a highly malignant childhood cerebellar tumor comprising molecularly and clinically distinct subgroups. Groups 3 and 4-MB originate from overlapping progenitor pools of the developing rhombic lip when neuronal differentiation hierarchies are subverted through somatic alterations. Mutations suspected to deregulate the activity of chromatin-modifying genes are pervasive in Group 3/4-MB. However, molecular consequences of these alterations remain largely undefined. We characterized the chromatin landscape of fifty-two primary MBs using chromatin immunoprecipitation followed by sequencing (ChIP-seq) for six histone modifications and performed multi-modal integration with sample-matched somatic lesions, genome-wide DNA methylation, and transcriptomic profiles. Analysis of differential chromatin states across MB subgroups revealed significant enrichment of the bivalent enhancer state (EnhBiv; marked by coincident H3K4me1 and H3K27me3) in Group 3/4-MB overlapping neurodevelopmental genes. Integrative bioinformatics coupled with CUT&RUN analysis revealed significant enrichment of KDM2B, a histone lysine demethylase overexpressed in Group 4-MB, in gene promoters marked by the EnhBiv state. CRISPR gene targeting or targeted protein degradation of KDM2B selectively suppressed growth of Group 3 and Group 4-MB models in vitro and in vivo, which was dependent on KDM2B DNA-binding domain but not demethylase activity. Acute and chronic KDM2B degradation impaired EZH2 recruitment through direct physical interactions and indirect KDM2B-mediated PRC1 activity, reducing H3K27me3 deposition and chromatin bivalency, while profoundly derepressing PRC2 targets involved in neuronal differentiation. Our comprehensive characterization of the MB chromatin landscape in a large cohort of primary tumors provides unprecedented insights into the epigenetic basis of MB subgroups, implicating novel mechanisms of tumorigenesis, and disclosing a unique subgroup-specific dependency conferred by KDM2B-mediated Polycomb activity that warrants consideration as a novel therapeutic target.
Authors
- Lena M. Kutscher (ORCID: https://orcid.org/0000-0002-1130-4582)
- Colleen A. Reilly (ORCID: https://orcid.org/0000-0003-3119-9940)
- Richa Bajpai
- Kyle S. Smith (ORCID: https://orcid.org/0000-0001-7143-7996)
- Jennifer L. Hadley (ORCID: https://orcid.org/0000-0003-1918-747X)
- Emily Darrow
- Qingsong Gao (ORCID: https://orcid.org/0000-0002-9930-8499)
- Rahul Kumar (ORCID: https://orcid.org/0000-0001-9671-1146)
- Shondra M. Pruett‐Miller (ORCID: https://orcid.org/0000-0002-3793-585X)
- Jamy C. Peng (ORCID: https://orcid.org/0000-0002-4043-8475)
- Taha Soliman (ORCID: https://orcid.org/0000-0003-3185-3092)
- Gang Wu (ORCID: https://orcid.org/0000-0002-1678-5864)
- Serap Erkek (ORCID: https://orcid.org/0000-0003-4439-5203)
- Brent A. Orr (ORCID: https://orcid.org/0000-0003-0997-4728)
- Priya Mittal (ORCID: https://orcid.org/0000-0001-6921-3934)
- Stefan M. Pfister (ORCID: https://orcid.org/0000-0002-5447-5322)
- Leena Paul (ORCID: https://orcid.org/0000-0003-4100-334X)
- Ruijie Xu (ORCID: https://orcid.org/0000-0003-3364-1587)
- Paul A. Northcott (ORCID: https://orcid.org/0000-0002-1220-5252)
- Melissa Batts (ORCID: https://orcid.org/0009-0007-3130-6570)
- Natarajan V. Bhanu (ORCID: https://orcid.org/0000-0002-1294-0062)
- Giles W Robinson (ORCID: https://orcid.org/0000-0001-7441-9486)
- Brian Gudenas (ORCID: https://orcid.org/0000-0002-9487-0300)
- Yurika Matsui (ORCID: https://orcid.org/0000-0003-0731-2499)
- Beisi Xu (ORCID: https://orcid.org/0000-0003-0099-858X)
- Hong Lin (ORCID: https://orcid.org/0000-0002-3048-8233)
- Jan O. Korbel (ORCID: https://orcid.org/0000-0002-2798-3794)
- Nadhir Djekidel
- Yiran Li (ORCID: https://orcid.org/0000-0001-7922-7766)
- Benjamin Aaron Garcia (ORCID: https://orcid.org/0000-0002-2306-1207)
- Xin Zhou (ORCID: https://orcid.org/0000-0003-3979-8200)
- KF Lowe
- Ran Tao (ORCID: https://orcid.org/0009-0001-4648-523X)
Institutions
- European Bioinformatics Institute (GB)
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- European Molecular Biology Laboratory (ES)
- Hopp Children's Cancer Center Heidelberg (DE)
- European Molecular Biology Laboratory (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/neuonc/noaf201.0022
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00